Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen, Deng-Chyang Wu
Tsung-Jung Lin, Department of Health care and Social Work, Taipei University of Marine Technology, New Taipei 25172, Taiwan
Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen, Department of Gastroenterology, Taipei City Hospital, Taipei 10629, Taiwan
Kuan-Yang Chen, Institute of Clinical Medicine, National Yang-Ming University, Taipei 11221, Taiwan
Kuan-Yang Chen, Institute of Neuroscience, National Chengchi University, Taipei 11651, Taiwan
Deng-Chyang Wu, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan
Deng-Chyang Wu, Division of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
Deng-Chyang Wu, Center for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
Author contributions: Lin TJ, designed the study and wrote manuscript; Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, collected data; Wu DC, offered the idea of this study and helped in literature review; Lin TJ, Chen KY designed and supervised the study and statistical analysis.
Institutional review board statement: This study was carried out according to the principles of the Declaration of Helsinki and was approved by the Institutional Review Board and ethics committee of Taipei City Hospital (TCHIRB-1011111).
Conflict-of-interest statement: The authors declare no conflict of interest relevant to this study. The article had been published as a poster in the meeting of Asia Pacific Digestive Week 2015 in Taiwan.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Kuan-Yang Chen, MD, Attending Doctor, Department of Gastroenterology, Taipei City Hospital, 11F., No. 10, Sec. 4, Renai Rd., Da-an District, Taipei 10629, Taiwan.
daa13@tpech.gov.tw
Telephone: +886-2-27093600-1159 Fax: +886-2-27047859
Received: June 9, 2018
Peer-review started: June 9, 2018
First decision: July 3, 2018
Revised: August 8, 2018
Accepted: August 30, 2018
Article in press: August 30, 2018
Published online: October 26, 2018
Processing time: 140 Days and 3.1 Hours
AIM
To evaluate the impact of cytochrome P450 2C19 (CYP2C19) and interleukin-1β (IL-1β) polymorphisms on the efficacy of Helicobacter pylori (H. pylori) eradication by using rabeprazole-based hybrid therapy.
METHODS
A total of 88 H. pylori-infected patients were recruited to receive 14-d of hybrid therapy from March 2013 to May 2014. Three patients were excluded from analysis because of incomplete compliance. Either a follow-up endoscopy or 13C-urea test was performed to determine the results of H. pylori eradication therapy. The genotypes of CYP2C19 and IL-1β were analyzed to investigate the impact on treatment effect.
RESULTS
The total eradication rate of H. pylori was 92.94% (79/85). According to the CYP2C19 genotypes, the rates of H. pylori eradication were 89.19% in extensive metabolizers (EM) and 95.83% in non-EM. The H. pylori eradication rates regarding the IL-1β genotypes were 92.59% in the normal acid secretion group and 93.10% in the low acid secretion group. After multivariable logistic regression analysis, both the genotypes of CYP2C19 and IL-1β had no significant influences on the eradication rates of H. pylori.
CONCLUSION
The CYP2C19 and IL-1β polymorphisms are not significantly independent factors of H. pylori eradication using rabeprazole-based hybrid therapy.
Core tip: In this study, we investigated the efficacy of hybrid therapy as a first-line treatment for Helicobacter pylori eradication and evaluated the independent predictor associated with eradication efficacy, including cytochrome P450 2C19, interleukin-1β (IL-1β)-511 polymorphism and antibiotic resistance. This study is pilot work investigating the impact of the IL-1β-511 polymorphism on the eradication rate of hybrid therapy.
